Leo-pharma A/s

Søren Christian Schou

Daniel Rodriguez Greve

Erik Rytter Ottosen

Simon Feldbæk Nielsen

Gunnar Grue-Sørensen

Carsten Ryttersgaard

Anthony Murray

Xifu Liang

Anette Graven Sams

Anne Marie Horneman

Kevin Neil Dack

Thomas Peter Sabroe

Sophie Elisabeth Havez

Tina Dahlerup Poulsen

Simon Felbdæk Nielsen

Jens Bjørn Jensen

The invention relates to compounds of general formula (I) wherein R, R, R, R, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immuno-suppression would be desirable for example in organ transplantation. 

Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof

The invention relates to compounds of general formula (I) wherein A, R, R, R, R, R, R, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation. 

Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors

The invention relates to compounds of general Formula (I), Wherein R, R, R, R, R, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation. 

Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof

The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer. 

Aminobenzophenone compounds

Growing community of inventors

Roskilde, Denmark

Søren Christian Schou